Skip to main content

A public-private consortium designs a new therapy to treat solid tumours



Emeritus Professor
Tel.+34 93 40 37125


Press & Communications Section Head
Tel.+34 93 40 37255

Expansión, El Periódico de Catalunya and Diario de Córdoba, among other media, have published articles about the biotechnologist Iproteos, a company created in 2011 by the scientists Teresa Tarragó and Ernest Giralt and based on the transfer of a technology developed atIRB Barcelona and the University of Barcelona (UB). The company has launched a project to develop a therapeutic strategy, designed by IBEC, to treat solid tumours, which account for 90-95% of cancer cases.

Link to El Periódico de Catalunya

Link to Diario de Córdoba


About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).